| The table shows significant references relating to the roles
of HGF/SF or Met in the types of cancer indicated. For each cancer type,
headings correspond to studies showing: HGF/SF expression in tumour biopsies;
Met expression in tumour biopsies; expression of HGF/SF or Met correlating with
poor prognosis; sporadic or germline-activating mutations in Met; tumour cells
in vitro expressing Met or HGF/SF, some with correlation to in vitro
neoplastic-like activities; and animal models supporting the role of Met and
HGF/SF in cancer, including human tumour xenografts in immunecompromised mice,
mice with HGF/SF or Met transgenes, or other animal models displaying
dependence on HGF/SF or Met in cancer development. A, autocrine; MFH, malignant
fibrous histiocytoma; %, percentage of tumours examined that are positive; N,
no report.
|
|